Support Article
Access and Availability of BAT Testing
BAT Testing is designed as a real-world plasma pathway for measuring Beta-Amyloid and Tau through clinical collection and certified laboratories. The goal is to make access practical in regular care settings, not limited to research-only workflows.
This page summarizes where access exists now, what supports comparability across sites, and how the network is expected to expand.
Global Accessibility
Current access is centered in the United States and Canada through certified partner pathways. The network model includes 200+ clinical collection partners and 400+ credentialed clinicians working under BATWatch standards.
Expansion planning includes Europe, Asia-Pacific, and Latin America, with broader rollout targets stated for 2026. Local availability can vary by region, provider participation, and laboratory readiness.
Availability Across Collection Settings
BAT Testing is offered through more than one collection path. Depending on region, this can include in-clinic blood draw, partner laboratory collection, and mobile phlebotomy support.
Using multiple collection pathways helps reduce location barriers while keeping the same plasma BAT Testing protocol.
Affordability and Predictability
The access model emphasizes cost transparency through a stated cost-cap framework. Pricing is intended to be disclosed in advance, with fewer surprise-fee patterns and no hidden laboratory upcharges.
The model also describes a no referral/commission structure between participating lab and pharmacy channels, with the user retaining control over sample-processing pathway options.
Standardization and Data Integrity
BAT Testing is framed around CLIA-certified laboratory handling, harmonized calibration, cross-lab verification, and recurring normalization practices. These controls are intended to keep results comparable across sites.
That comparability is important for longitudinal follow-up, where the value comes from tracking the same markers over time.
The Future of Access
Planned growth focuses on broader international lab partnerships, expanded mobile and direct-to-patient logistics, and interoperability with existing EHR and research data environments.
The direction is to make plasma Beta-Amyloid and Tau monitoring easier to repeat over time while maintaining consistency standards.
Key Takeaway
Access to BAT Testing is built around three operational pillars: practical availability, standardized laboratory comparability, and cost transparency.
Together, these make plasma Beta-Amyloid and Tau monitoring more usable for ongoing brain health follow-up.